Government-run Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed to prevent heart problems, but policy experts said Government-run Medicare patients are still likely to encounter significant barriers getting access to the highly popular and expensive drug.
Government-run Medicare previously wasn’t reimbursing for Wegovy, since the federal payer is legally barred from covering weight loss drugs. But the Food and Drug Administration this month approved Wegovy for preventing heart problems in people with obesity and heart disease, leading many to suspect that Government-run Medicare would start covering the drug for this usage.
Makers of obesity drugs have been hoping that showing additional benefits beyond weight loss would induce more insurers to cover them. Government-run Medicare’s guidance, first reported Thursday, moves in that direction, but experts point out that the private insurers that administer Government-run Medicare’s prescription drug benefit — called Part D — can still choose to not include Wegovy on their formularies, especially if they think it would be too costly.
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.